Rise and shine, everyone, the middle of the week is already here. Time flies when you’re having … fill in the blank here. Meanwhile, a hazy, muggy morning is unfolding here on the Pharmalot campus, where the official mascot is noisily snoozing and the short people are otherwise gainfully occupied. As for us, we are downing yet another needed cup of stimulation. Our choice today is coconut. No kidding. Feel free to join us, as always. And here are some tidbits to help you along. Have a wonderful day and keep in touch …

A combination of AstraZeneca’s (AZN) lung cancer drug Imfinzi and an experimental treatment failed to extend the lives of patients with stage 4 non-small cell lung cancer and high levels of gene mutations, Reuters reports. The late-stage clinical trial was testing Imfinzi along with another treatment called tremelimumab and compared the combination to platinum-based chemotherapy to treat patients whose cancer had spread beyond the lungs. The study did not meet the main goal of improving overall survival in the primary group.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Kudos to our scribe for a fulsome Pharmalittle. Indeed, “a much welcomed fillip” at the beginning of the business day. (And I needed to look that word up to be sure it wasn’t a typo – you learn something new here every day, yes?}

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy